脂质组学特征可区分MASLD与MetALD
BACKGROUND: The recent consensus statement redefined steatotic liver diseases. Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction and alcohol-related liver disease (MetALD) now represent distinct disease entities.…
要点
- 在预测MetALD对比MASLD的前30个差异脂质标志物中,多数与HDL相关,并在两个分析时间点均显著富集。
- 前五位代谢物为乙酰乙酸、3-羟基丁酸、大HDL中的磷脂、大HDL颗粒浓度、大HDL中的游离胆固醇。
- 孟德尔随机化分析进一步证实饮酒与HDL相关代谢物水平升高相关。
核心结论
- 以HDL为中心的脂质组学标志物,尤其是较大与中等HDL亚组分中的标志物,可能区分MetALD与MASLD。
- 需进一步纵向与实验研究验证这些发现并评估其临床意义。
研究设计与样本
- 基于英国生物银行数据集,分析40534名有可用MRI肝脏扫描者。
- 分析250项血浆脂质组与代谢组参数,并用孟德尔随机化分析确认饮酒与脂质组学生物标志物的关联。
主要发现
- 比较预测MetALD对比MASLD的前30个差异表达脂质组学生物标志物,多数与HDL相关,并在两个分析时间点均显著富集。
- 前五位代谢物为:乙酰乙酸、3-羟基丁酸、大HDL中的磷脂、大HDL颗粒浓度、大HDL中的游离胆固醇。
- 比较酒精相关肝病与MASLD的敏感性分析显示相似关联,提示HDL特征随时间稳定。
- 孟德尔随机化分析进一步证实饮酒与HDL相关代谢物水平升高相关。
局限性
- 需进一步纵向与实验研究验证这些发现并评估其临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recent consensus statement redefined steatotic liver diseases. Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction and alcohol-related liver disease (MetALD) now represent distinct disease entities. However, biomarkers that differentiate MASLD and MetALD remain largely unknown. AIMS: To identify lipidomic biomarkers with discriminatory potential for distinguishing MetALD from MASLD. METHODS: Using the UK Biobank dataset, 40,534 people with available MRI liver scans were analysed. A total of, 11,217 cases with a proton density fat fraction (PDFF) ≥ 5% were identified as having steatotic liver disease. Among these, lipidomic profiles were obtained for 5539 MASLD and 462 MetALD cases. A total of, 250 plasma lipidomic and metabolomic parameters were analysed. Mendelian randomisation (MR) analysis was used to confirm the association between alcohol consumption and the lipidomic biomarkers. RESULTS: When comparing the top 30 differentially expressed lipidomic biomarkers predicting MetALD compared to MASLD, the majority were related to HDL and were significantly overrepresented at both analysed time points. The top five metabolites were: acetoacetate, 3-hydroxybutyrate, phospholipids in Large HDL, concentration of large HDL particles, free cholesterol in large HDL. The sensitivity analysis comparing alcohol-related liver disease to MASLD revealed similar associations, suggesting that the HDL signature is stable over time. Additionally, MR analysis further confirmed that alcohol consumption was associated with increased levels of HDL-related metabolites. CONCLUSION: Our findings indicate that HDL-centric lipidomic markers, particularly those within the larger and medium HDL subfraction, may differentiate MetALD from MASLD. Further longitudinal and experimental studies are warranted to validate these findings and assess their clinical implications.
引用
- Schneider KM, Cao F, Huang HYR, et al. The Lipidomic Profile Discriminates Between MASLD and MetALD. Aliment Pharmacol Ther. 2025. PMID: 39935287. doi:10.1111/apt.70012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。